Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure Clinical presentation of daclizumab side effects with skin rash and meningoencephalomyelitis Clinical presentation of daclizumab side effects with.

Published byBeatrix Richardson Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure Clinical presentation of daclizumab side effects with skin rash and meningoencephalomyelitis Clinical presentation of daclizumab side effects with."— Presentation transcript:

1 Figure Clinical presentation of daclizumab side effects with skin rash and meningoencephalomyelitis
Clinical presentation of daclizumab side effects with skin rash and meningoencephalomyelitis (A) Skin rash of the neckline. (B and C) MRI shows multiple actively contrast-enhancing MS-like lesions with distinct perifocal edema. (D and E) Additionally diffuse cerebellar edema is present accompanied by infratentorial leptomeningeal enhancement indicative of meningeal and cerebellar inflammation. Resulting mass effect and occlusive hydrocephalus required suboccipital decompression (E). Also note simultaneous cervical cord inflammatory lesion. (F) Complete resolution of perifocal edema after disease remission. Note the right frontal hemorrhagic biopsy defect. (G–J) Biopsies of cerebellar meninges (G) and a right frontal lesion (H–J) show a pronounced inflammatory infiltrate. HE staining depicts meningitis with numerous T cells, plasma cells, and eosinophilic granulocytes (G). Histology of the right frontal lesion reveals a demyelinated lesion (H). Again, dominant inflammation, consisting of CD4- and CD8-positive T cells (I, anti-CD8), CD138-positive plasma cells (J, anti-CD138), and eosinophilic granulocytes, is evident. Inflammatory cells densely infiltrate vessel walls, resembling vasculitis. In addition, pronounced parenchymal inflammation is evident. HE = hematoxylin/eosin, LFB/PAS = luxol fast blue/periodic acid-Schiff. Scale bars: G = 100 μm, H = 1 mm, and I (valid for I and J) = 200 μm. Franziska Scheibe et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e479 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Download ppt "Figure Clinical presentation of daclizumab side effects with skin rash and meningoencephalomyelitis Clinical presentation of daclizumab side effects with."

Similar presentations

Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Brain MRI findings in the present case

Figure 1 Brain MRI findings in the present case
Figure MRI of anti-MOG-IgG–associated myelitis

Figure MRI of anti-MOG-IgG–associated myelitis
Figure 2 Spinal cord lesions

Figure 2 Spinal cord lesions
Figure Neuroimaging and pathology

Figure Neuroimaging and pathology
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.

Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 3 Example of venous narrowing

Figure 3 Example of venous narrowing
Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.

Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.
Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.
Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.

Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.
Figure 4 Detection of EBER+ cells in MS and control brains by in situ hybridization Detection of EBER+ cells in MS and control brains by in situ hybridization.

Figure 4 Detection of EBER+ cells in MS and control brains by in situ hybridization Detection of EBER+ cells in MS and control brains by in situ hybridization.
Figure Nuclear Nrf2 expression after fumarate therapy A new left occipital fluid-attenuated inversion recovery hyperintense (A), T1 hypointense (B), and.

Figure Nuclear Nrf2 expression after fumarate therapy A new left occipital fluid-attenuated inversion recovery hyperintense (A), T1 hypointense (B), and.
Figure 1 Linear relationship between CSF inflammation and glucose in meningitis; analysis stratified by diagnostic category (aseptic, n = 115 and microbial,

Figure 1 Linear relationship between CSF inflammation and glucose in meningitis; analysis stratified by diagnostic category (aseptic, n = 115 and microbial,
Figure 1 Histopathologic features of case 1 (A–G) and case 2 (H–L)‏

Figure 1 Histopathologic features of case 1 (A–G) and case 2 (H–L)‏
Figure 1 Quantitative spinal cord MRI maps and segmentations

Figure 1 Quantitative spinal cord MRI maps and segmentations
Figure 5 Increased frequency of parenchymal CD138- and LMP-1–positive cells in MS Increased frequency of parenchymal CD138- and LMP-1–positive cells in.

Figure 5 Increased frequency of parenchymal CD138- and LMP-1–positive cells in MS Increased frequency of parenchymal CD138- and LMP-1–positive cells in.
Figure 2 Neuropathology of PML lesions in a patient with MS treated with fingolimod Neuropathology of PML lesions in a patient with MS treated with fingolimod.

Figure 2 Neuropathology of PML lesions in a patient with MS treated with fingolimod Neuropathology of PML lesions in a patient with MS treated with fingolimod.

Similar presentations

Ads by Google